Thread by @HadidiSamer

My top 7 #ASCO24 abstracts to watch for #mmsm

Will have more details on those once presented/published- those are initial thoughts that may evolve according to more data

There are more interesting data will highlight during the meeting

@ASCO

🧵

#mmsm #ASCO24
1️⃣ IMROZ: Isa-VRd vs VRd i n transplant-ineligible NDMM pts

➡️
✅ follow-up: 5 years

✅Median PFS Isa-VRd(NR, estimated 7.5 years!!) vs VRd(4.5 years)

🛑 Grade 5 TEAE: 2 times higher with Isa-VRd (11% vs 5.5%) meetings.asco.org/abstracts-pres…

#mmsm #ASCO24
Thoughts on IMROZ

Very important data

✅median PFS: 7.5 yrs(estimated)
✅Grade IV AEs: higher though compare to:

MAIA: Dara-Rd: median F/U <5yrs (shorter median follow up),death related to AEs (10%) in Dara-Rd👇

#mmsm #ASCO24
Thoughts on IMROZ

🛑baseline characteristics: will be important

For MAIA trial:

- 43% of pts >=75 yrs 👇

- Median PFS:NR was not reached (95% CI 54·8–NR) - at least more than 4.5 years

We will need the complete data

#mmsm #ASCO24

2️⃣BENEFIT/IFM2020-05

The added benefit of weekly Velcade is not (yet) reflected by improved PFS/OS

➡️

✅ median age: 73 yrs, 1 out of 3 pts >75 yrs
✅ median follow-up: 21 months
✅Deeper responses👇
🛑1 of 3 pts with grade ≥2 neuro AEs meetings.asco.org/abstracts-pres…

#mmsm #ASCO24
Thoughts on BENEFIT

✅We may not need a quad (usual V dosing) in most transplant in-eligible patients

✅Anti-CD38 +Rd is really a great option for most patients

✅Will be looking for high risk groups and older pts to see if quad helps this subset of patients

#mmsm #ASCO24
3️⃣DREAM-7: BVd vs DVd

➡️
✅ Median PFS: BVd(3 yrs) vs. DVd (1 yr)

✅ In high-risk cytogenetic subgroup, PFS was 33 mo with BVd vs 11 mo with DVd

🛑 Ocular AEs more frequent with BVd vs DVd (79% vs 29%)

DREAM-8: interesting (N/A-LBA n=8️⃣)meetings.asco.org/abstracts-pres…

#mmsm #ASCO24
Thoughts on DREAM-7

✅Addition of belantamab mafodotin to PI (V) showed better PFS in randomized trial (anti-CD38 based)

✅benefit maintained in high risk disease

🛑AEs (mainly ocular) &censoring will be imp to explore- this requires full data (hopefully soon)

#mmsm #ASCO24
4️⃣ CARTITUDE-4 subgroup analysis

➡️

Difficult to treat pts(functionally high risk)

✅Better PFS with Cilta cel vs SC

✅1-yr PFS for Cilta cel: 77% vs 49%

✅Better responses 👇 meetings.asco.org/abstracts-pres…

#mmsm #ASCO24
Thoughts on CARTITUDE-4 subgroup analysis

🛑This subgroup of pts remain with sub-optimal outcomes: Meaning 1 out of 4 pts who got Cilta cel earlier with functionally high risk progressed in <= 1 year

✅ Access to Cilta Cel earlier for this group is imp

#mmsm #ASCO24
5️⃣ PERSEUS MRD data

➡️

✅ Rates of sustained MRD neg for ≥12 mo were higher for D-VRd vs VRd

- 10-5: 2 out of 3 compared to 1 out of 3
- 10-6: 1 out of 2 compared to 1 out of 5 meetings.asco.org/abstracts-pres…

#mmsm #ASCO24
thoughts on PERSEUS MRD data

✅ Addition of anti-CD38 to induction/maintenance regimen showed improvement with long term sustained disease control

🛑We need to follow patients for >10-15 years in such important studies to better know the long term outcomes

#mmsm #ASCO24
6️⃣MRD2STOP

➡️

✅ treatment discontinuation study

✅Median follow up after discontinuation: 2.5 years

✅ ~10% of pts progressed after discontinuation (90% didn’t)

✅ 3-year PFS was 85%meetings.asco.org/abstracts-pres…

#mmsm #ASCO24
Thoughts about MRD2STOP

🛑Many pts didn’t qualify to stop tt (need of MRD -ve), some of those may do well with discontinuation

🛑Data on high risk will be imp to see.

🛑Longer follow up and more pts needed

#mmsm #ASCO24
7️⃣ T cell subsets as predictors of response to BCMA BsAbs

➡️

✅79 pts treated with BCMA BsAb

✅ Increased proportion of CD4 cells within the ALC is significantly associated with better response to BCMA targeting bsAb (absolute no. Not impmeetings.asco.org/abstracts-pres…

#mmsm #ASCO24

Will be looking forward to meet many colleagues, mentees, mentors and share some other important presentations @ASCO

Make sure you stop by Trainee lounge for important trainees/early career sessions @ASCOTECAG @HemOncFellows

End 🧵